Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1999-06-09
2000-07-11
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
5142362, 5142378, 514278, 514315, A61K 31675, A61K 31535, A61K 3144, A61K 314445
Patent
active
060873485
ABSTRACT:
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant therapy with other anti-stress agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
REFERENCES:
patent: 5162339 (1992-11-01), Lowe, III
patent: 5496833 (1996-03-01), Baker et al.
patent: 5538982 (1996-07-01), Hagan et al.
patent: 5576317 (1996-11-01), Gonsalves
patent: 5612337 (1997-03-01), Baker et al.
patent: 5716942 (1998-02-01), Dorn et al.
patent: 5719147 (1998-02-01), Dorn et al.
patent: 5728695 (1998-03-01), Harrison et al.
patent: 5919781 (1999-07-01), Baker et al.
patent: 5952315 (1999-09-01), Baker et al.
Roccon, et al., Pharmacological Research, 1995, 31, 191.
Shaikh, M., et al., Brain Research, 1993, 625, 283-294.
Shirayama, Y., et al., Brain Research, 1996, 739, 70-78.
Siegel, R., et al., Neurochem. Int., 1984, 6(6), 783-789.
Siegel, A., et al., Aggressive Behavior, 1995, 21, 49-62.
Teixeira, R., et al., European J. Pharm., 1996, 311, 7-14.
Vassout, et al., Neuropeptides, 1994, 26 (Suppl. 1), 38.
Wahlestedt, Science, 1998, 281, 1624-1625.
Wall Street Journal, Aug. 13, 1998, B1, Col. 2.
Aguiar, M., et al., Physiology & Behavior, 1996, 60 (4) 1183-1186.
Barden, N., et al., J. Neurochem., 1983, 41, 834-840.
Brodin, E., et al., Neuropharmacology, 1987, 26 (6) 581-590.
Brodin, E., et al., Neuropeptides, 1994, 26, 253-260.
Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885-891.
Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87.
Elliot, P. J., Exp. Brain Res. UK, 1988, 73, 354-356.
F-D-C Reports--Prescription Pharmaceuticals and Biotechnology, Dec. 8, 1997, 59 (49), 10.
File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747-752.
Kramer, et al., Science, 1998, 281, 1640-1645.
Lowe, J., et al., Drug News Perspect, 1992, 5 (4), 223.
Malek-Ahmadi, Neuroscience and Behavioral Reviews, 1992, 16, 365-359.
Rimon, R., et al., Biological Psychiatry, 1984, 19 (4), 509-516.
Culman et al., Chemical Abstracts, vol. 126, Abstract No. 140188(1985).
Ikeda et al., Chemical Abstracts, vol. 123, Abstract No. 336513 (1984).
Okano et al., Chemical Abstracts, vol. 122, Abstract No. 262813 (1983).
Baker Raymond
Curtis Neil Roy
Elliott Jason Matthew
Harrison Timothy
Hollingworth Gregory John
Henley III Raymond
Merck Sharp & Dohme Ltd.
Rose David L.
Thies J. Eric
LandOfFree
Use of NK-1 receptor antagonists for treating stress disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of NK-1 receptor antagonists for treating stress disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of NK-1 receptor antagonists for treating stress disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-542577